[2-(2-Chloro-ethoxy)-phenyl]-acetic Acid Ethyl Ester | 521300-33-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: [2-(2-Chloro-ethoxy)-phenyl]-acetic Acid Ethyl Ester
• 英文别名: ethyl 2-[2-(2-chloroethoxy)phenyl]acetate
• CAS: 521300-33-4
• 化学式: C₁₂H₁₅ClO₃
• 分子量: 242.702
• InChiKey: PKLCHEAMZORRHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [2-(2-Chloro-ethoxy)-phenyl]-acetic Acid Ethyl Ester 在 盐酸 、 sodium hydride 作用下， 反应 13.67h， 生成 2-[2-(1-imidazolyl)ethoxy]phenylacetic acid hydrochloride
  参考文献：
  名称：

  Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles

  摘要：

  1-(2-Phenoxyethyl)-1H-imidazole was found to be an inhibitor of thromboxane (TxA2) synthetase, but it also inhibited the adrenal cytochrome P-450 enzyme steroid 11 beta-hydroxylase. The preparation of a series of analogues is described, and activity against TxA2 synthetase, PGI2 synthetase, cyclooxygenase, and steroid 11 beta-hydroxylase is discussed. Potency against TxA2 synthetase was increased by introduction of a carboxyl group at a suitable distance from the imidazole ring. A distance of 8.1-8.8 A between N-1 of the imidazole and the carboxyl carbon was found to be optimal. Introduction of a carboxyl group also had the effect of reducing activity against steroid 11 beta-hydroxylase. The most potent and selective compound was found to be 4-[2-(1H-imidazol-1-yl) ethoxy]benzoic acid (14).

  DOI：

  10.1021/jm00148a009
• 作为产物：
  描述：

  苯磺酸2-氯乙酯 以 N-甲基乙酰胺 为溶剂， 生成 [2-(2-Chloro-ethoxy)-phenyl]-acetic Acid Ethyl Ester
  参考文献：
  名称：

  PDE9 inhibitors for treating cardiovascular disorders

  摘要：

  该发明涉及用于治疗心血管疾病的PDE9抑制剂。首选的PDE9抑制剂是具有以下结构的化合物，其中R1是H或C1-6烷基，其中R1连接到N1或N2中的任一者；R2是C1-6烷基，可选择地被羟基或烷氧基取代；C3-7环烷基，可选择地被烷基、羟基或烷氧基取代；饱和的5-6成员杂环，可选择地被烷基、羟基或烷氧基取代；het1或Ar1；R3是C1-6烷基，可选择地被从Ar2中独立选择的1或2个基团取代；C3-7环烷基，可选择地被C1-6烷基取代；OAr2；SAr2；NHC(O)C1-6烷基；het2；黄酮；和萘。

  公开号：

  US20030195205A1

文献信息

• Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
  申请人：——

  公开号：US20040023989A1

  公开（公告）日：2004-02-05

  This invention is directed to a method of treating insulin resistance syndrome (IRS), hypertension and/or type 2 diabetes in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor or a pharmaceutical composition thereof. This invention is also directed to such methods wherein said cGMP PDE9 inhibitor is used in combination with other agents to treat IRS, hypertension and/or type 2 diabetes.

  本发明涉及一种治疗哺乳动物中胰岛素抵抗综合症（IRS）、高血压和/或2型糖尿病的方法，包括向该哺乳动物施用cGMP PDE9抑制剂或其制剂。本发明还涉及这样的方法，其中所述的cGMP PDE9抑制剂与其他药物联合使用以治疗IRS、高血压和/或2型糖尿病。
• CROSS, P. E.;DICKINSON, R. P.;PARRY, M. J.;RANDALL, M. J., J. MED. CHEM., 1985, 28, N 10, 1427-1432
  作者：CROSS, P. E.、DICKINSON, R. P.、PARRY, M. J.、RANDALL, M. J.

  DOI：——

  日期：——
• TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1444009A1

  公开（公告）日：2004-08-11
• US6967204B2
  申请人：——

  公开号：US6967204B2

  公开（公告）日：2005-11-22
• [EN] TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS<br/>[FR] TRAITEMENT DU SYNDROME DE RESISTANCE A L'INSULINE AINSI QUE DU DIABETE DU TYPE 2 AU MOYEN D'INHIBITEURS DE LA PHOSPHODIESTERASE 9 (PDE9)
  申请人：PFIZER PROD INC

  公开号：WO2003037432A1

  公开（公告）日：2003-05-08

  This invention is directed to a method of treating insulin resistance syndrome (IRS), hypertension and/or type 2 diabetes in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor or a pharmaceutical composition thereof. This invention is also directed to such methods wherein said cGMP PDE9 inhibitor is used in combination with other agents to treat IRS, hypertension and/or type 2 diabetes.